U.S., Aug. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07783308) titled 'A Phase I Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD4144' on Aug. 20.
Brief Summary: This Phase I, open-label, parallel group study will investigate the single oral dose PK, safety, and tolerability of AZD4144 to male and female participants with mild, moderate, and severe hepatic impairment compared to matched controls with normal hepatic function.
Study Start Date: Aug. 24
Study Type: INTERVENTIONAL
Condition:
Hepatic Impairment
Intervention:
DRUG: AZD4144
Single oral dose of AZD4144 in participants from all groups
Recruitment Status: NOT_YET_RECRUITING
S...